-

07:54:37 AM

STTK Stock News

STTK - Shattuck Labs Inc

03/16/23 8:31 AM

Nasdaq : STTK

clinical trial

Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Shattuck Labs, Inc. (Shattuck) (NASDAQ:

RHEA-AI

neutral

03/01/23 7:00 AM

Nasdaq : STTK

Shattuck Labs Announces Participation in Upcoming March Conferences

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and

RHEA-AI

neutral

02/23/23 4:30 PM

Nasdaq : STTK

earnings

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinical trial of SL-172154 in acute myeloid leukemia (AML) and

RHEA-AI

neutral

02/16/23 7:00 AM

Nasdaq : STTK

conferencesearnings

Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune

RHEA-AI

neutral

02/09/23 6:01 AM

Nasdaq : STTK

Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune

RHEA-AI

neutral

01/09/23 7:00 AM

Nasdaq : STTK

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune

RHEA-AI

neutral

11/08/22 4:30 PM

Nasdaq : STTK

earnings

Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights

– Completed enrollment in Phase 1 dose-escalation clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer; complete data expected midyear 2023 – – Dosed first patient in ongoing Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in

RHEA-AI

neutral

11/07/22 8:00 AM

Nasdaq : STTK

clinical trial

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Shattuck Labs, Inc.

RHEA-AI

neutral

11/03/22 8:30 AM

Nasdaq : STTK

Shattuck Labs Announces Participation in Upcoming November Conferences

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and

RHEA-AI

neutral

11/01/22 4:30 PM

Nasdaq : STTK

conferencesearnings

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and

RHEA-AI

neutral

1 2 3 4 5 6 Next